Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Data sharing and evaluation.

R A McPherson1

  • 1Scripps Immunology Reference Laboratory, Scripps Clinic and Research Foundation, La Jolla, California 92121.

Cancer
|March 15, 1992
PubMed
Summary
This summary is machine-generated.

Standardizing molecular cancer marker assays is crucial for accurate diagnosis and staging. Method validation ensures reliable transfer of new cancer marker technologies from research to clinical practice.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36  TeV with the ATLAS Detector at the LHC.

Physical review letters·2025
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
See all related articles

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Clinical Diagnostics

Background:

  • Interinstitutional evaluations of cancer markers require standardized assays for valid clinical comparisons.
  • New cancer marker assays rely on understanding biochemical functions and measurement technologies.

Purpose of the Study:

  • To outline the essential components of method validation for new cancer marker assays.
  • To ensure the accurate and rapid implementation of novel diagnostic assays in clinical settings.

Main Methods:

  • Method validation involves detailing assay principles, reagents, calibration, and sensitivity.
  • It includes assessing assay behavior, specimen needs, and correlations with clinical data.
  • Quality control, proficiency testing, and interpretation guidelines are critical.

Related Experiment Videos

Main Results:

  • Comprehensive method validation provides specific data on assay performance.
  • It establishes the reliability and reproducibility of new diagnostic tests.
  • Standardized validation facilitates comparison across different laboratories.

Conclusions:

  • Fulfilling all method validation components guarantees accurate implementation of new diagnostic assays.
  • Standardization is key for reliable cancer marker evaluation in clinical studies and practice.
  • Robust validation accelerates the adoption of innovative cancer diagnostics.